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Abstract
Triple antiplatelet therapy (TAPT, or triple therapy), is an
oral medication regimen designed to reduce the risk of major cardiovascular events. It consists of aspirin, clopidogrel
or an alternative, and an oral anticoagulant (OAC). It differs
from dual antiplatelet therapy (DAPT) due to inclusion of an
OAC. Multiple clinical studies have indicated that triple therapy is more effective at clot prevention, when compared to
aspirin monotherapy and DAPT, but is associated with a
higher risk of major bleeding. Pharmacists have a key role in
determining candidates for DAPT and TAPT regimens. Other
opportunities for pharmacists include patient monitoring,
counseling and medication review throughout treatment
with antithrombotic therapy.
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Introduction
Dual antiplatelet therapy (DAPT) consists of aspirin and
clopidogrel (or an alternative). It is used to prevent thrombosis and inhibit platelet function for patients with coronary
artery disease (CAD), atherosclerotic ischemic stroke, atrial
fibrillation (AF) or acute coronary syndrome (ACS) with or
without percutaneous coronary intervention (PCI). 1 However, the introduction of an additional antiplatelet agent to the
regimen leads to an increased risk of bleeding when compared to aspirin monotherapy. In a study comparing the effectiveness of aspirin alone to a DAPT (aspirin-clopidogrel)
regimen, there was a statistically significant decrease (95
percent confidence interval (CI): 0.59-0.82, p < 0.05) in the
incidence of stroke among those on DAPT. 2
Development of triple antiplatelet therapy (TAPT, or triple
therapy) has led to controversy over the ideal number of
antiplatelet/anticoagulant agents to provide the best efficacy for clot prevention while maintaining safety. The components of TAPT are aspirin, clopidogrel or an alternative, and
warfarin.3 Alternative antiplatelets to clopidogrel in either
therapy include prasugrel and ticagrelor. Clopidogrel is a
thienopyridine antiplatelet agent that acts by irreversibly
blocking the P2Y 12 adenosine di phosphate (ADP) receptors
on the platelet surface.4 This prevents activation of certain
complexes that cause platelet aggregation. Since this action
is irreversible, platelet aggregation is reduced.
Prasugrel has a similar mechanism of action to clopidogrel.5
A clinical trial assessed therapeutic outcomes using prasugrel in comparison to clopidogrel in patients with myocardial

infarction (MI). The primary endpoints were death from
cardiovascular (CV) causes, nonfatal MI and nonfatal stroke.
The secondary outcomes were stent thrombosis and
planned PCI for patients enrolled in the study with acute
coronary syndrome. The results of this study showed that
there was a reduced death rate from MI for subjects taking
prasugrel compared to those taking clopidogrel. However,
the prasugrel group experienced increased bleeding (1.4
percent in the prasugrel group versus 0.9 percent in the
clopidogrel group, p=0.01).5 Prasugrel is a more potent inhibitor of platelet aggregation than clopidogrel due to higher
exposure of the metabolite to the receptor. It is wellabsorbed and metabolized by the body and inhibits platelet
aggregation within 30 minutes of administration. In comparison, clopidogrel has a median onset of inhibition of 1.5
hours. 6 It is suggested to weigh the benefits of prasugrel as
an antiplatelet agent against its risks for bleeding as compared to clopidogrel.
Another antiplatelet agent used in place of clopidogrel is
ticagrelor which acts via reversible inhibition of the P2Y 1 2
ADP receptor.7 Ticagrelor has been shown to have greater
inhibition of the receptor than clopidogrel. In a study comparing the efficacy and safety of ticagrelor and clopidogrel in
patients hospitalized for ACS, ticagrelor decreased rates of
death due to vascular MI and stroke more than clopidogrel,
with a hazard ratio of 0.84 (p < 0.001, 95 percent CI [0.770.92]).7 Clopidogrel and ticagrelor did not differ in risk of
bleeding, while prasugrel showed more intracranial and gastrointestinal bleeding than ticagrelor.5 This indicates that
ticagrelor may be more effective as an antiplatelet agent,
without the adverse effect of increased bleeding, as compared to clopidogrel and prasugrel.
An oral anticoagulant (OAC) is added to prevent stroke and
other CV events. Despite the added benefits, traditional
OACs introduce risks to the regimen, including an increased
risk for bleeding, which can lead to worse health outcomes
and decreased compliance.3 However, an OAC exhibits greater anticoagulation than aspirin and clopidogrel combined.a
Novel oral anticoagulants (NOACs) may serve as alternatives
to warfarin in the TAPT regimen.9 Several NOACs have been
investigated in TAPT, including dabigatran, apixaban and
rivaroxaban. Dabigatran is a factor Ila (thrombin) inhibitor,
and apixaban and rivaroxaban are factor Xa inhibitors. Using
NOACs over warfarin may be beneficial because NOACs are
not vitamin K antagonists and have fewer side effects. There
is also a lower risk of bleeding associated with some NOACs
when compared with warfarin. In a study comparing warfarin to dabigatran, rate of major bleeding was 3.57 percent
per year in the warfarin group and 2.78 percent per year in
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the dabigatran group (p=0.003). 9 The more traditional vitamin K antagonists do have a reversal option as vitamin K can
be administered in the event of a bleed. 10 While there is a
reversal agent for dabigatran (idarucizumab), there is currently no reversal agent for rivaroxaban or apixaban. Another risk associated with NOACs is liver injury, with reports
that 1.8 to 3.9 percent of patients taking these medications
experience unpredictable and severe liver injury or liver failure.11
Therapy Selection
Appropriate candidates for TAPT are PC! patients with stents
implanted either electively or to treat ACS.3 A patient with
stent implantation requires DAPT because monotherapy
with aspirin is insufficient to prevent thrombosis. Triple antiplatelet therapy may be suitable for these patients if they
have a low risk of bleeding. Other candidates for TAPT include those with conditions that require stroke prevention as
well as antiplatelet therapy, such as AF patients with ACS or
mechanical valve patients with severe CAo.12.13
Percutaneous coronary intervention with stent implantation
(PCI-s) has become a routine procedure for many individuals
with myocardial ischemia.14 In patients with AF who have
undergone PCl-s, the decision to recommend TAPT is based
on prevention of cardioembolic events associated with AF
and stent thrombosis after PCI-s in addition to an assessment
of bleeding risk. Combined aspirin-clopidogrel therapy is less
effective in preventing stroke than OAC alone, but OAC alone
is insufficient to prevent stent thrombosis.a Thus, TAPT is
often recommended. In 2010, the European Society of Cardiology (ESC) published a consensus document with the recommendation that all patients with AF who undergo PCI-s
should receive TAPT for at least one month and up to 12
months, depending on the type of stent used, the clinical indication (elective stent implantation versus ACS) and the patient's risk of hemorrhage. 14 After bare metal stent (BMS)
implantation, triple therapy should be utilized for two to four
weeks followed by OAC monotherapy.a Drug-eluting stents
(DES), on the other hand, require three to six months of triple therapy followed by OAC monotherapy. Secondgeneration and third-generation DES may be preferred as
they might be associated with shorter re-endothelialization
times and shorter duration of triple therapy. However, the
use of BMS is the ultimate preference in this population as
the recommended duration of triple antithrombotic therapy
is considerably shorter.14
Individually, antiplatelet and anticoagulant agents increase a
patient's risk of bleeding, and, when used in combination,
they further worsen this risk. A meta-analysis consisting of
nine clinical trials that included 1,996 participants found that
TAPT is associated with a twofold increase in major bleeding
complications after PCI-s compared to DAPT in patients with
an indication for long-term OAC.14 Major bleeding was defined as an absolute decrease in hematocrit of more than 15
percent, the need for transfusion of two or more units of
blood, the need for corrective surgery, the occurrence of an
intracranial or retroperitoneal hemorrhage or any combina-
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tion of the aforementioned events.a Almost all reported major bleeding events occurred in the first six months of follow
up and were often associated with supratherapeutic international normalized ratio (INR) levels. Additionally, most
bleeding events occurred in the gastrointestinal (GI) system
of patients with baseline anemia. Another study that examined 4,959 patients over the age of 65 with acute MI and AF
who underwent coronary stenting found that incidence of
bleeding requiring hospitalization within two years postdischarge as well as incidence of intracranial hemorrhage,
were significantly higher for patients discharged on TAPT
compared to DAPT.1s
Specific mechanisms contributing to increased bleeding associated with triple therapy have not yet been studied but are
likely affected by various clinical and therapeutic factors
such as advanced age, female gender, peri-interventional
administration of glycoprotein lib/Illa inhibitors, smoking
and high prevalence of comorbidities including renal dysfunction and previous major bleeding.a In the event that a
major bleeding event should occur while a patient is on
TAPT, treatment should be aggressive. If minor bleeding
events occur (defined as observed blood loss and 9 to 15
percent decrease in hematocrit or decrease in hemoglobin
level<':40 g/L if no bleeding is identified), antithrombotic
therapy should not be discontinued because of the patient's
increased risk of developing stent thrombosis or vascular
throm boem bol ism.
For patients in whom a NOAC is used in place of warfarin in
TAPT therapy, the lowest dose effective for stroke prevention in AF should be considered. 16 A meta-analysis involving
30,866 patients with recent ACS concluded that the inclusion
of a NOAC in a triple therapy regimen increased the bleeding
risk by 79 to 134 percent while minimally decreasing recurrent ischemic events in patients without AF. Several other
studies were conducted that evaluated triple therapy with
rivaroxaban, apixaban or dabigatran combined with aspirin
and clopidogrel in patients with ACS. Rivaroxaban was tested
using subtherapeutic doses (2.5 mg twice daily or 5 mg daily)
for complete anticoagulation because higher doses were
found to produce a dose-dependent increase of bleeding
risk.17,1a For this reason, use of rivaroxaban may not be preferred in triple therapy. 16 Unlike rivaroxaban, apixaban in
triple therapy was studied in doses recommended for complete anticoagulation.19 The study was stopped prematurely
because there was a significant 2.5-fold increase in risk of
bleeding among the apixaban group compared to the placebo
group with no indication of benefit in preventing MI, stroke
or CV death.13 Thus, triple therapy with apixaban may not be
preferred. Dabigatran in triple therapy was also found to be
associated with dose-dependent increase of bleeding risk in
patients with ACs.20 A substudy analysis of the RE-LY
(Randomized Evaluation of Long-Term Anticoagulation
Therapy) study was conducted to further assess the bleeding
risk of dabigatran in TAPT by comparing dabigatran 110 mg,
dabigatran 150 mg, and warfarin.21 This study determined
that dabigatran 110 mg twice daily is noninferior to warfarin,
with fewer bleeding incidents regardless of concomitant an-
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tiplatelet use in patients with AF. While the relative risk of
bleeding was found to be similar with dabigatran 110 mg,
dabigatran 150 mg, and warfarin, the absolute risk was lowest with dabigatran 110 mg. Overall, bleeding risk must be
assessed and monitored with all NOACs.
Despite the risks, TAPT is a viable option to consider for
many patients, especially those with a higher risk of thrombotic events and a lower risk of bleeding events.a Conducting
a risk assessment of bleeding and ischemic complications is
highly advised for all patients who are candidates for TAPT.
Triple therapy should not be continued long-term after PCl-s
in patients with a high bleeding risk profile as even mild to
moderate bleeding events are associated with poorer longterm prognosis. However, lowering the dosage of aspirin to
less than or equal to 100 mg/day in the triple therapy regimen may reduce the occurrence of major or minor bleeding
events.22 In patients with low risk of bleeding complications,
TAPT should be highly considered as the elective antithrombotic drug treatment approach.a
In spite of being associated with increased risk of bleeding,
TAPT has been found to be more efficacious in lowering
mortality in patients with AF and PCI compared to DAPT in
addition to reducing major adverse CV events, including
death or hospital readmission for Ml, ischemic stroke or
hemorrhagic stroke.15 The meta-analysis discussed previously consisting of nine clinical trials demonstrated a 40 percent relative reduction in major adverse cardiac events and a
41 percent relative reduction in all-cause mortality. 14 Reduction in major adverse CV events is due to the lower occurrence of thrombotic and embolic events in the TAPT group.a
Furthermore, reduction in all-cause mortality occurs as a
direct result of significant reduction in major adverse CV
events in the triple therapy group. One retrospective study
conducted in Spain by Ruiz-Nodar et al. supports this conclusion.23 The study included a cohort of 426 patients with AF
who underwent PCl-s, 50 percent of whom were discharged
on TAPT and 40.8 percent of whom were discharged on
DAPT. Upon completion of a multivariate analysis, it was
found that patients who received TAPT had a lower all-cause
mortality rate (17.8 percent versus 27.8 percent, p=0.002)
and lower major adverse cardiac event rate (26.5 percent
versus 38.7 percent, p=0.001) compared to patients receiving DAPT.

Therapy Considerations and the Role of the Pharmacist
Due to the high risk of bleeding, the 2014 American College
of Cardiology and the American Heart Association Task
Force on Practice Guidelines recommends refraining from
the long-term use of TAPT due to exponential increase in
bleeding risk.24 Additionally, DAPT is recommended to be
utilized after PCI. However, the 2016 ESC Guidelines recommend the use of an OAC after stenting in patients with a history of deep vein thrombosis and pulmonary embolism and
in AF patients with a stroke risk. This expert-based consensus suggests that TAPT should be used in these patients but
only for a short duration.16 Based on the ESC guidelines, clinical judgment influenced by thrombotic risk should be used
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to determine whether or not therapy should be supplemented by an OAC.
When the TAPT regimen is selected, regular monitoring for
bleeding risk is advised upon discharge. Pharmacists play a
critical role in the monitoring process, especially when the
OAC of choice is warfarin. Upon discharge, patients on warfarin should be referred for anticoagulation monitoring so that
the INR can be assessed regularly. INR is a key indicator of
bleeding risk in those patients who are receiving warfarin.e
Because of this increased bleeding risk with TAPT, the target
range is lower and narrower than a typical warfarin treatment plan. The recommended goal INR for these patients is
2.0 to 2.5 as compared to the typical therapeutic INR range
of 2.0 to 3.Q. 16,2 4-25 This narrower INR range for TAPT
patients is recommended but with low evidence since this
target INR range has not been evaluated in many patient
populations and is based solely on expert opinion.24 Pharmacists may also utilize the HAS-BLED method for assessment
of other disease states and lifestyle factors to monitor risk of
bleeding in select patients. The HAS-BLED method is based
on seven factors: hypertension, abnormal renal/liver function, stroke, bleeding history or predisposition, labile INR,
elderly and drugs/alcohol concomitantly which all contribute to the risk of bleeding for an AF patient.14
Discussion with TAPT patients is necessary so that health
care providers can identify potential drug interactions,
adverse effects, effective ways to educate and other drug
therapies a patient is using. This necessary information is
obtained best by addressing patient concerns, asking openended questions, listening to patient responses in their entirety and assessing patient adherence based on previous
medical history.14 In particular, warfarin is known to have
many drug interactions that can be identified by talking to
patients. All patients should be educated regarding warfarin's potential to react with specific medications, which
could result in altered effects of warfarin. A common list of
medications that interact with warfarin should be provided
to patients. Additionally, the patient should receive education on how to identify bleeding risks with the biggest identifier as bruising. 14 In order to prevent GI bleeds, the use of
proton pump inhibitors (PPis), Hz antagonists and antacids
is common in TAPT patients and is recommended in patients
with a history of GI bleeding.16,2 4 ,26 However, close monitoring is advised to ensure efficacy because clopidogrel and
PPis are metabolized by CYP2Cl 9 which can decrease the
effects of clopidogrel due to competitive binding. While being treated with TAPT that includes clopidogrel, patients
should only be on PP Is if there is a specific indication to treat
a disease state such as chronic heartburn or if it will benefit
the patient by protection from GI bleeding.26These discussions can happen in anticoagulation clinics, in community
pharmacies and prior to discharge at the hospital.
Pharmacists must work with other health care providers to
promote the continuum of care for each patient, especially
while in the hospital. Pharmacists have a role in the medication reconciliation process before and after PC! to ensure
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that TAPT candidates will receive the best and safest outcomes while on the therapy. Even though pharmacists in anticoagulation clinics will be assessing the INR of patients on
warfarin after discharge, assessment of CHADS2 scores for
stroke risk in AF patients, INR monitoring and HAS-BLED are
critical while in the hospital. 14 For those patients on NOACs,
HAS-BLED remains an effective monitoring tool. All of this
information should be communicated with all health care
providers involved with the care of each patient.
Conclusion
Overall, when choosing a treatment regimen for a patient in
need of anticoagulation therapy, it is important to evaluate
the benefits of using TAPT as well as its risks in comparison
to DAPT. While TAPT has shown to be more effective at preventing thrombosis, the increased risk of bleeding may cause
harm in patients who are already at high risk to develop
bleeds. However, TAPT is recommended for specific patient
populations such as patients with ACS undergoing PCI-s or
patients with a mechanical heart valve with severe CAD as
these patients require more aggressive anticoagulation
therapy. This recommendation is based on expert opinion. In
order to obtain evidence-based recommendations, further
research needs to be done comparing long-term outcomes of
TAPT and DAPT in various patient populations. The safety of
patients on TAPT is dependent on careful monitoring of
treatment by health care professionals and thorough patient
education about medication adherence, proper medication
usage and the warning signs of bleeding.
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